For AI assistants & researchers — machine-readable summary of this page
What this page is: Delvantic's full research page for Veeva Systems Inc. (VEEV) — AI-driven forensic equity research: mechanical valuation models (DCF, EPV, anchored-PE, scenario) plus three independent AI lenses (Quality / Value / Sentiment). Everything below is rendered server-side; you are not missing content that requires JavaScript. All scores are predictions and research opinions, not financial advice.
Our current read (analysis of 2026-08-23): Designation Watch · Gem Score +4 (−100…+100 Quality+Value blend) · Quality 82 · Value -59 · Sentiment 52 (timing only, not weighted) · Composite fair value $43.82 vs $247.90 at analysis
Page map (sections in order; each card carries a stable
reference-name attribute you can cite):
profile-header/price-overview— company profile, live quote, market capextended-analysis— the core: three AI lens reads with findings, scores, and the analyst memofuture-predictions— our forward price-band predictionsmarket-narrative/ai-findings/gpt-critique— narrative context, cross-model findings, and an adversarial critique of our own analysis (near the end of the document)- Members-only sections (render as login gates for anonymous readers):
price-history,income-trend,key-metrics,financials(statement tables),insider-trading. The analysis above is public; the raw data tables require a free account.
More for machine readers: site briefing at
/llms.txt ·
any ticker resolves at delvantic.com/stock/TICKER ·
raw inputs are public-company filings and market data (via licensed data feeds);
every model, score, lens read, and prediction on this page is Delvantic's own analysis.
Veeva Systems Inc.
VEEV NYSEVeeva Systems Inc. is a cloud software company focused on the life sciences industry. It provides industry-specific applications that help pharmaceutical, biotechnology, and other healthcare organizations manage customer relationships, clinical operations, quality processes, regulatory content, and commercial activities within a compliant digital environment. The company’s platform is designed to support critical workflows across development, manufacturing, and go-to-market functions, with products that emphasize data integrity, collaboration, and regulatory alignment. Veeva Systems serves a broad range of life sciences customers, from emerging biotech firms to global pharmaceutical companies, and plays a significant role in the modernization of software systems used across healthcare and regulated industries.
Price Overview
Price History (1 Year)
Revenue & Net Income Trend
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
EPS (Diluted): 5.44
Total Equity: $7.21B
Shares: 166,995,000
Total Debt: $0.00
Cash: $1.42B
EBITDA: N/A
Total Debt: $0.00
Cash: $1.42B
Revenue: $3.20B
Revenue: $3.20B
Revenue: $3.20B
Total Equity: $7.21B
Tax Rate: 23.9%
Equity: $7.21B
Total Debt: $0.00
Cash: $1.42B
Current Liabilities: $1.64B
Long-Term Debt: $0.00
Total Debt: $0.00
Total Equity: $7.21B
Shares: 166,995,000
Shares: 166,995,000
CapEx: $0.00
Shares: 166,995,000
Stock Price: $247.90
Net Income: $908.91M
Industry Benchmarks
Income Statement (Annual)
Last updated: Aug 22, 2026 4:27pm (1d ago)| Metric | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Revenue | $1.9B | $2.2B | $2.4B | $2.7B | $3.2B |
| Cost of Revenue | $503.7M | $609.4M | $677.3M | $699.6M | $782.0M |
| Gross Profit | $1.3B | $1.5B | $1.7B | $2.0B | $2.4B |
| Operating Expenses | $841.6M | $1.1B | $1.3B | $1.4B | $1.5B |
| Operating Income | $505.5M | $459.1M | $429.3M | $691.4M | $916.4M |
| Net Income | $427.4M | $487.7M | $525.7M | $714.1M | $908.9M |
| EBITDA | $531.5M | $484.1M | $454.3M | — | — |
| EPS | $2.79 | $3.14 | $3.27 | $4.41 | $5.55 |
| EPS (Diluted) | $2.63 | $3.00 | $3.22 | $4.32 | $5.44 |
Balance Sheet (Annual)
Last updated: Aug 22, 2026 4:08pm (1d ago)| Metric | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Cash & Equivalents | $1.1B | $886.5M | $703.5M | $1.1B | $1.4B |
| Total Current Assets | $3.1B | $4.0B | $5.0B | $6.3B | $8.0B |
| Total Assets | $3.8B | $4.8B | $5.9B | $7.3B | $9.0B |
| Current Liabilities | $840.8M | $1.0B | $1.2B | $1.4B | $1.6B |
| Long-Term Debt | — | — | — | — | — |
| Total Liabilities | $904.8M | $1.1B | $1.3B | $1.5B | $1.8B |
| Total Equity | $2.9B | $3.7B | $4.6B | $5.8B | $7.2B |
| Retained Earnings | $1.7B | $2.2B | $2.7B | $3.5B | $4.4B |
Cash Flow (Annual)
Last updated: Aug 22, 2026 4:27pm (1d ago)| Metric | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Operating Cash Flow | $764.5M | $780.5M | $911.3M | $1.1B | $1.4B |
| Capital Expenditure | — | — | — | — | — |
| Free Cash Flow | — | — | — | — | — |
| Acquisitions (net) | -$7.8M | $0 | $0 | — | — |
| Net Debt Issued / (Repaid) | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | — | — | $0 | $0 | -$169.9M |
| Net Change in Cash | $409.5M | -$251.6M | -$183.0M | $414.3M | $302.4M |
Growth Trends (YoY %)
Last updated: Aug 22, 2026 4:27pm (1d ago)| Metric | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Revenue Growth | +16.4% | +9.7% | +16.2% | +16.3% |
| Gross Profit Growth | +14.7% | +9.1% | +21.4% | +17.9% |
| Operating Income Growth | -9.2% | -6.5% | +61.0% | +32.5% |
| Net Income Growth | +14.1% | +7.8% | +35.8% | +27.3% |
| EBITDA Growth | -8.9% | -6.1% | — | — |
Deep Analysis
Risk : Reward — if the last quarter repeats
Live · as of 2026-08-22 16:36Even the bull case prices 48% below today — the ratio here measures the model-vs-market gap, not payoff odds. Another quarter like the worst recent one costs 64%.
| Case | Growth | Margin | Fair value | vs price ($247.90) |
|---|---|---|---|---|
| Bull — recovery | +24% | 32.6% | $129.69 | -48% |
| Base — stabilizes | +16% | 28.4% | $89.82 | -64% |
| Bear — keeps slipping | +8% | 24.1% | $60.61 | -76% |
| Stress — last quarter repeats | +16% | 28.5% | $90.24 | -64% |
Narrative Economics
market-narrative step).
Growth Outlook
Analyzed 2026-08-22 16:34The question every valuation on this page silently assumes: is this company likely to grow? Judged forward — the business, its category, the world — against what's already printed.
Claude Reading
Looking at the raw quarterly cadence first: revenue went $676M → $699M → $721M → $759M → $789M → $811M → $836M → $883M over eight quarters. That's not decelerating in any meaningful sense — YoY growth by quarter is roughly 25.4%→27.3%→16.0%→16.0%→16.3%→16.0%→16.1%→16.3%. The step-down happened a year ago (CRM Salesforce transition/pricing normalization) and growth has since re-anchored at a remarkably stable ~16%. Net margin has walked from 25% to 29.6% — real, sustained, and running hotter than the annual net margin figure of 28.4% suggests. TTM revenue is ~$3.32B, TTM net income ~$941M, so the trailing P/E is closer to ~43x, not the terrifying number implied by the DCF-shortfall framing. Operating CF of $1.42B on $3.20B revenue is a 44% CFO margin — this is elite unit economics, not a house of cards.
Now to the model stack: the Valuation Synthesis "fair value $43.82" is nonsensical for a business generating $1.4B of operating cash flow with zero debt and $1.4B of cash — that would imply an EV/CFO of ~5x for a 16%-grower with 76% gross margins and net-cash balance sheet. The Narrative model's "82% of price is narrative" framing inherits this same broken anchor. I dissent from the magnitude of the synthesis dissent. That said, the Market Forces and Thesis Evaluation reads are directionally right: at 12.3x EV/sales and ~43x TTM earnings, the stock does embed durable 15%+ growth AND continued margin expansion. A more honest reverse-DCF: to justify $248, you need ~14% revenue CAGR for a decade fading to 4%, ~35% terminal FCF margins, and a ~9% discount rate. That gets you to roughly $180–210 fair value. Not $46, not $248. Overvalued by ~20–30%, not by 80%.
The contrarian case against my own moderation: Veeva's Salesforce CRM divorce (moving to Vault CRM) is a genuine live risk that the models underweight — this is a multi-year migration where a competitor (Salesforce itself, plus IQVIA OCE) can attack the installed base. If even 10-15% of CRM revenue defects, the "sticky moat" story cracks and the multiple compresses fast. Second, ROIC of 12% and ROE of 12.6% are surprisingly pedestrian for a "best-in-class SaaS compounder" — the equity base has ballooned to $7.2B, meaning capital efficiency is fading even as margins expand. Third, insider activity: eight sales in the last two months, zero open-market buys, is not "neutral" — it's the standard pattern of insiders quietly derisking into strength. Fourth, the pre-flight classification as "traditional/mature earner" is right but underlines the problem: mature earners don't deserve 43x P/E multiples unless growth genuinely re-accelerates, and there's no evidence in the quarterly print that it will.
GPT Reading
Veeva looks like exactly what great software businesses are supposed to look like in their mature phase: clean revenue compounding, very high gross margins, rising operating leverage, and a fortress balance sheet. Revenue went from $1.85B in FY2022 to $3.20B in FY2026, a 15%-16% annualized clip, while net income more than doubled from $427M to $909M. What stands out most is not just growth but quality of growth. Quarterly revenue has stepped up from $676.2M to $882.9M over the last eight reported quarters, and net margins stayed mostly in a tight 25%-30% band, finishing at 29.6% in the latest quarter. Annual gross margin at 75.5% and operating margin at 28.7% tell you this is not buying growth with undisciplined spend. Operating cash flow of $1.42B on $3.20B of revenue is exceptional conversion, and with $1.42B of cash and no debt, the business has almost no balance-sheet risk.
The story in the numbers is that Veeva has already crossed from “promising vertical SaaS” into “elite compounder,” and that matters because many valuation frameworks badly undershoot companies that sustain both growth and very high incremental margins for long periods. The jump in annual operating income from $429M in FY2024 to $691M in FY2025 and $916M in FY2026 is especially important: revenue grew 16%-17%, but operating income grew 60% and then 33%, implying meaningful leverage is still available even at scale. The recent quarterly run-rate supports that view. Latest-quarter revenue of $882.9M annualizes above $3.5B, about 10% ahead of the FY2026 base, and that is before assuming further expansion through the year. A business with near-30% net margins, no leverage, and double-digit top-line growth should not be valued like a generic “mature earner.” The rule-based label catches the maturity, but misses that this company is still compounding faster and more profitably than most mature software peers.
That said, I still come out cautious on the stock, not the company. At roughly $40.3B market cap, investors are paying about 13x trailing sales and 45.6x earnings for a business growing revenue around 16% and earnings around 27%. Those are strong numbers, but not rare enough to justify pretending execution risk is absent. The latest four quarters sum to about $3.32B of revenue and roughly $969M of net income, so the stock is also around 41x current run-rate earnings despite already having reached an unusually high margin structure. Once a software company is already at 28%-30% net margins, future earnings growth has to lean more on revenue than margin expansion, and that usually compresses multiples over time. I do not buy the absurdly low synthesized fair value in the briefing; a $46 stock price would imply the market should value Veeva like a low-quality cyclical, which is nonsense. But I do think today’s price already discounts a lot of durability, and probably a return to sustained mid-teens growth with little volatility.
The best argument against my caution is straightforward: Veeva may deserve a permanent scarcity premium because the fundamentals are unusually resilient and getting better, not worse. Quarterly revenue did not roll over; it accelerated from $720.9M to $759.0M to $789.1M to $811.2M to $836.0M to $882.9M. Net income likewise climbed from $171.0M eight quarters ago to $260.9M now. If the business can keep compounding revenue in the mid-teens while preserving ~30% net margins and converting cash at current rates, a 40x-45x earnings multiple is expensive but not irrational for a debt-free category leader. A smart bull would also point out that ROIC and ROE look modest only because the balance sheet carries excess cash and the business is conservatively capitalized; on an operating basis, this is a much stronger franchise than the raw returns ratios suggest. I weigh that argument seriously, but the problem is that buying at $248 requires confidence not just in business quality, but in the market continuing to award a premium multiple to that quality.
What would change my mind is either price or proof of renewed growth. If Veeva can push quarterly revenue above $950M while holding net margin near 30%, that would indicate the current valuation is being grown into faster than I expect. Similarly, a full-year revenue trajectory approaching $3.7B-$3.8B with operating margin above 29% would support a more constructive stance even at a premium multiple. On the other hand, if growth slips toward low teens while margins simply hold flat, the stock is vulnerable because there is no valuation cushion here. My bottom line: phenomenal company, demanding stock, and not nearly as overvalued as the extreme model outputs imply, but still priced above what I’d want to pay.
Grok Reading
Veeva’s numbers describe a high-quality vertical software compounder that has cleanly transitioned from earlier hypergrowth into a predictable mid-teens machine. Annual revenue climbed from $1.85B in FY2022 to $3.20B in FY2026, a 16.3% CAGR that matches the most recent year-over-year print; the last eight quarters march upward without interruption—from $676M to $883M—while net margins have settled in the high-20s and just printed 29.6% on $883M of revenue. Operating income nearly doubled from $429M to $916M over three years as the gross margin held above 75% and operating leverage kicked in; net income of $909M and operating cash flow of $1.42B on a debt-free balance sheet with $1.42B cash and a 4.9 current ratio confirm both earnings quality and fortress finances. ROE and ROIC in the low-12% range look modest only because the equity base is large and unlevered; the economic engine itself is efficient. The story the data tell is durable franchise economics inside life-sciences workflow and compliance software, not a fading growth story.
Where the quantitative models go off the rails is the composite fair-value print near $46. That figure implies a mid-single-digit earnings multiple on nearly $1B of net income and $1.4B of cash generation—an absurdity for any sticky SaaS business with 16% growth, 28%+ net margins, and zero leverage. The 45.6× P/E, 13× sales and 12.3× EV/revenue are undeniably rich, yet they are the market’s way of capitalizing a mission-critical moat and high switching costs, not a 80% overvaluation mirage. Revenue growth has been remarkably stable rather than collapsing, earnings are still compounding at 27–31%, and the Rule-of-40 score sits near 44. The deceleration flag is real but mild; this is maturation, not deterioration.
The strongest contrary case is straightforward: at $248 you are paying roughly 45× trailing earnings and 13× sales for mid-teens growth that the models correctly note leaves almost no margin of safety if CRM saturation slows the mix or if larger cloud platforms nibble at the edges. A smart opponent would also highlight that the entire $200-plus premium above a conservative DCF rests on the narrative of perpetual platform monopoly and TAM expansion that has not yet shown up as acceleration in the reported numbers. Insider activity is a steady drip of option-related sales, offering no endorsement. Those points have force; I simply weigh the cash-flow durability and margin structure more heavily than a pure multiple-compression scare, and I refuse to anchor on a $46 output that treats Veeva like a no-growth industrial.
I would flip to a more constructive stance if the next two quarters re-accelerate revenue growth above 18–20% with Vault contribution visibly lifting the mix, or if the company begins returning meaningful capital while holding net margins above 30%. Conversely, two consecutive quarters of revenue growth slipping under 12% or operating margin compression would confirm the multiple is simply too high and push me firmly into the bear camp.
Big-3 Panel — where each AI stands
Advanced Analysis Forensic deep-dive · separate lenses
Revenue compounds from $1.85B (FY22) to $3.20B (FY26), a ~15% CAGR, with gross margin expanding from 72.8% to 75.5% and operating margin recovering from a 2024 trough of 18.2% back to 28.7%. Net income nearly doubled over four years to $908.9M and FCF grew from $764.5M to $1.42B, so cash generation actually exceeds GAAP earnings (OCF/NI 1.64x, accruals -6.4% of assets). Beneish M of -2.62 and Altman Z of 15.92 corroborate that reported numbers are real. Balance sheet is a fortress: $1.42B liquid cash, zero net debt, and one year of FCF equals current cash balance - the business is entirely self-funding with no external capital dependency. Dilution is well controlled for a software company: diluted shares crept from 162.3M to 167.0M (0.7% CAGR) despite SBC running 14.8% of revenue, though buybacks recover only ~9% of SBC so per-share value is preserved rather than actively returned. Insider tape is routine: option-exercise-and-sell and tax-withholding activity, with only $10M of sales in 12 months against a $40B cap - immaterial and not a red flag. The business is a mature earner with expanding, not compressing, unit economics.
Verify before trusting this (5)
- Customer concentration and any life-sciences CRM churn/renewal metrics in the 10-K
- Progress and cost of migrating Vault CRM off Salesforce infrastructure
- Segment split between R&D (Vault) vs Commercial and growth rates within each
- RPO/backlog trend and net revenue retention if disclosed
- Any change in buyback authorization vs SBC run-rate going forward
The composite fair value of $43.82 and signal-adjusted $46.27 are almost certainly runaway-low outputs of an EPV floor method that ignores Veeva's mid-teens growth and 100%+ cash conversion — I discount them heavily rather than take the implied -81% at face value. But even generously re-anchoring: at ~$40B market cap on a business doing high-single-digit-billions of revenue with ~30%+ FCF margins, the stock trades near the top of vertical-SaaS multiples (roughly 12-14x sales, 30x+ forward EBIT). That is a full-quality price for a fortress-quality asset — the gap the value lens is paid to find isn't here. For $247.90 to be cheap, you need Veeva to durably grow mid-teens for a decade-plus with margins still expanding and no meaningful commercial-cloud share loss to Salesforce's replacement product. That is the bull case, not a margin of safety. The bear framing — 'priced for perfection, minimal room for disappointment' — matches the tape. Deserved value on skeptical-but-fair assumptions sits somewhere in the $180-215 range; today's price is a 15-30% premium to that. Not egregiously overvalued, but no discount to underwrite.
Verify before trusting this (4)
- Development Cloud vs Commercial Cloud growth split and any CRM churn commentary
- FY26 subscription revenue guide and operating-margin trajectory
- Net-revenue-retention disclosure and Vault platform attach rates
- SBC as % of revenue and buyback pace vs dilution
VEEV is riding a genuinely hot narrative right now: platform-monopoly archetype with strong intensity, freshly reinforced by Eli Lilly committing to Vault CRM globally - exactly the kind of anchor-customer proof point that keeps the 'critical infrastructure for life sciences' story intact. The stock is up ~34% in a month, analyst fair-value estimates are being nudged UP (245 to 251), and the news flow is almost uniformly constructive, with the Q2 print as the next reflexive catalyst. That is a tailwind, not a mania. The tape itself is mildly risk-on but jittery (VIX 15, off recent highs), and macro is a soft headwind (10y 4.69%, market PE 25.7) - normally a modest drag on a premium-multiple SaaS name. But VEEV's 0.92 beta and healthcare-software profile blunt that; it is not a high-beta unprofitable story stock that gets mauled on rate ticks. The bigger latent risk is that 82% of the price is narrative premium per the story-vs-fundamentals gap, so any Q2 wobble or AI/CRM competitive whisper could crack the story fast - but as of today the narrative is winning and pressing the stock up.
Verify before trusting this (5)
- Q2 print reaction - especially subscription revenue and Vault CRM/Development Cloud commentary
- Whether more top-20 pharma follow Lilly onto Vault CRM (or any defect to Salesforce Life Sciences Cloud)
- AI-disruption chatter aimed at vertical SaaS - if that narrative rotates onto VEEV, the premium compresses fast
- Sell-side target revisions in the two weeks post-earnings
- Any rotation out of premium-multiple software into value/cyclicals
Life sciences IT spend is being reallocated rather than cut: pharma is trimming commercial headcount and legacy services while still funding compliance, trial digitization and data infrastructure — the parts Veeva sells. Macro headwinds (10y at 4.69) squeeze emerging-biotech formation, which is the marginal customer cohort, and IRA pricing pressure keeps large-pharma budgets disciplined. Net: the world supports steady mid-teens compounding for a validated, regulation-anchored system of record, but it no longer supports the 25-30% land-grab growth of the last cycle. AI is the genuine two-sided variable — it can expand Veeva's per-customer value (AI agents on proprietary regulated data) or deflate the content/services layer it monetizes today.
When we made this prediction on Aug 23, 2026, VEEV was $247.90. We expect it to be $228.00 by Feb 2027, and we consider it great value under $190.00. This is an early model (v0.6.0) — the direction is more reliable than the exact price. Made Aug 23, 2026.
Blue is our prediction, starting the day we made it. Grey is a slower route to the same place — the same destination, taking longer. Black is the actual price, so you can see how we are doing.